EUVIMEDEUVIMED entdecken
Crossref

The Immunotherapeutic Target ANLN Promotes Renal Clear Cell Carcinoma by Regulating PI3K /Akt and P53 Signaling Pathways

Li Shan, Guo-Jian Gu, Cheng-Cheng Xiang, Er-Dong Zuo, Lian Lian, Xu Cheng iD

BioFactors · 2025

DOI: 10.1002/biof.70023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioFactors, 2025. Verfasst von Li Shan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Yangzhou University, Jiangsu, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Proto-Oncogene Proteins c-akt, Tumor Suppressor Protein p53, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: the basic research program for medical and health applications of the Taicang Science and Technology Bureau of Jiangsu Province, Medical and Health Technology Research Project of the Taicang Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of Anillin (ANLN) in clear cell renal cell carcinoma (ccRCC) is not well understood. This study aimed to investigate the possible function and mechanism of ANLN in ccRCC. By using data from the Cancer Genome Atlas (TCGA), we assessed ANLN expression in various cancers. Furthermore, the GEPIA database was used to analyze survival rates, pathway enrichment, and immune infiltration. Experiments were employed to study how ANLN expression affects tumor cell apoptosis, migration, invasion, and proliferation. Protein blotting was conducted to evaluate apoptosis, proliferation, epithelial mesenchymal transition (EMT), and the expression of proteins linked to the PI3K/AKT and P53 signaling pathways. mRNA levels of ANLN were notably increased in diverse cancer tissues, as shown in the TCGA database, a finding that was also observed in ccRCC patients. Remarkably, high ANLN levels were associated with lower pathologic grades and a worse survival prognosis in ccRCC patients. In vitro experiments revealed that knockdown of ANLN in ccRCC cells led to reduced proliferation, migration, invasion, and EMT. Additionally, ANLN seemed to impact immune evasion and increase the likelihood of distant metastasis based on immune infiltration analyses. The use of PI3K/AKT pathway inhibitors or P53 signaling pathway agonists was effective in reducing the invasive behavior of ccRCC and correcting immunosuppression. Overall, ANLN could be a valuable prognostic indicator for the survival of ccRCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellProto-Oncogene Proteins c-aktTumor Suppressor Protein p53Phosphatidylinositol 3-KinasesKidney NeoplasmsMicrofilament ProteinsHumansSignal TransductionCell ProliferationCell MovementEpithelial-Mesenchymal TransitionCell Line, TumorGene Expression Regulation, NeoplasticApoptosisPrognosisMaleFemale

Stichwörter der Autor:innen

AKT kinase inhibitorANLNKIRCbioinformaticsimmune signalingimmunotherapy

Substanzen

Proto-Oncogene Proteins c-aktTumor Suppressor Protein p53Phosphatidylinositol 3-KinasesTP53 protein, humanMicrofilament Proteins

Autor:innen und Institutionen

  • Yangzhou University, Jiangsu, China.
  • Department of Oncology and Radiation, The First People's Hospital of Taicang, Jiangsu, China.
  • Department of Pathology, The First People's Hospital of Taicang, Jiangsu, China.
  • Department of Oncology, Suzhou Xiangcheng People's Hospital, Xiangcheng Clinical School, Yangzhou University Medicine Colloge, China.

ORCID-Profile: Xu Cheng

Förderung

  • the basic research program for medical and health applications of the Taicang Science and Technology Bureau of Jiangsu Province
  • Medical and Health Technology Research Project of the Taicang Science and Technology Bureau

Zitieren

APA

Shan, L., Gu, G. J., Xiang, C. C., Zuo, E. D., Lian, L., & Cheng, X. (2025). The Immunotherapeutic Target ANLN Promotes Renal Clear Cell Carcinoma by Regulating PI3K /Akt and P53 Signaling Pathways. BioFactors. https://doi.org/10.1002/biof.70023

Vancouver

Shan L, Gu GJ, Xiang CC, Zuo ED, Lian L, Cheng X. The Immunotherapeutic Target ANLN Promotes Renal Clear Cell Carcinoma by Regulating PI3K /Akt and P53 Signaling Pathways. BioFactors. 2025. doi:10.1002/biof.70023

BibTeX
@article{Shan2025,
  author = {Shan, Li and Gu, Guo-Jian and Xiang, Cheng-Cheng and Zuo, Er-Dong and Lian, Lian and Cheng, Xu},
  title = {The Immunotherapeutic Target ANLN Promotes Renal Clear Cell Carcinoma by Regulating PI3K /Akt and P53 Signaling Pathways},
  journal = {BioFactors},
  year = {2025},
  doi = {10.1002/biof.70023}
}
Kostenlos starten →